Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
Portfolio Pulse from
Johnson & Johnson has acquired Intra-Cellular Therapies, Inc., enhancing its neuroscience portfolio. The acquisition includes CAPLYTA, an FDA-approved treatment for bipolar I and II depression and schizophrenia.
January 13, 2025 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intra-Cellular Therapies, Inc. has been acquired by Johnson & Johnson, which includes its FDA-approved drug CAPLYTA for bipolar and schizophrenia treatment.
The acquisition by a major company like J&J is likely to positively impact ITCI's stock in the short term due to the premium typically paid in such deals.
CONFIDENCE 95
IMPORTANCE 95
RELEVANCE 100
POSITIVE IMPACT
Johnson & Johnson has acquired Intra-Cellular Therapies, Inc., which includes CAPLYTA, an FDA-approved treatment for bipolar and schizophrenia, strengthening its neuroscience portfolio.
The acquisition of Intra-Cellular Therapies and its drug CAPLYTA is likely to enhance J&J's position in the neuroscience market, potentially boosting its stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 80